FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
02/19/2026
Back to search
Official data from USPTO
ABOGENBIO
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
33
Latest update
02/20/2026
Trademark type
Combined
Nice classes
5, 42
Filing date
11/01/2021
Registration date
07/15/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/15/2025
Last transaction
02/20/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
5
Owner type
99
Owner location
CN
Examiner
HARMON, RAYMOND E
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of the stylized wording "ABOGENBIO".
Holders and representatives
Holders
Suzhou Abogen Biosciences Co., Ltd.
Representatives
THOMAS HOXIE HOXIE & ASSOCIATES LLC
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for the treatment or prevention of cancerinfectious diseases; chemico-pharmaceutical preparations for the treatment or prevention of cancer and infectious diseases; drugs being pharmaceutical preparations for medical purposes for the treatment or prevention of cancer and infectious diseases; biological preparations for the treatment or prevention of cancer and infectious diseases for medical purposes; medicines for the treatment or prevention of cancer and infectious diseases for human purposes; chemical preparations for medical purposesfor the treatment or prevention of cancer and infectious diseases; crude drug being homeopathic pharmaceuticals for the treatment of infectious viral diseases;lipid particle for nucleotide drug delivery purpose for the treatment or prevention of cancer and infectious diseases; and biochemical medicines for the treatment or prevention of cancer and infectious diseases; dietetic substances being foods and beverages adapted for medical use for the treatment or prevention of cancer and infectious diseases
Class 42
Technological research in the field of medical researchspecifically for the treatment or prevention of cancer and infectious diseases; quality controlspecifically for products for the treatment or prevention of cancer and infectious disease; product quality testingspecifically for products for the treatment or prevention of cancer and infectious diseases; cancer research for medical purposes; pharmaceutical drug development servicesspecifically for pharmaceutical drugs for the treatment or prevention of cancer and infectious diseases; pharmaceutical product evaluationdrug evaluationspecifically for the treatment or prevention of cancer and infectious diseases; pharmaceutical research servicesspecifically for products for the treatment or prevention of cancer and infectious diseases; medical researchspecifically for the treatment or prevention of cancer and infectious diseases; development of pharmaceutical preparations and pharmaceuticalsspecifically for products for the treatment or prevention of cancer and infectious diseases
Publications
History of USPTO decisions and trademark events.
33 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
02/05/2026
FIMP
FINAL DISPOSITION PROCESSED
02/05/2026
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/15/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
07/15/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
07/15/2025
TMBN
TTAB RELEASE CASE TO TRADEMARKS
06/24/2025
OP.T
OPPOSITION TERMINATED NO. 999999
06/24/2025
OP.D
OPPOSITION DISMISSED NO. 999999
06/24/2025
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
06/19/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
05/31/2023
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
05/31/2023
RFNT
REFUSAL PROCESSED BY IB
04/19/2023
OP.I
OPPOSITION INSTITUTED NO. 999999
03/27/2023
OPNS
OPPOSITION NOTICE (IB REFUSAL) SENT TO IB
03/22/2023
OPNC
OPPOSITION NOTICE (IB REFUSAL) CREATED
03/22/2023
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
12/15/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/22/2022
PUBO
PUBLISHED FOR OPPOSITION
11/22/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/02/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/18/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/18/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/18/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/18/2022
RFNT
REFUSAL PROCESSED BY IB
09/12/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
08/23/2022
RFRR
REFUSAL PROCESSED BY MPU
08/23/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
08/17/2022
CNRT
NON-FINAL ACTION WRITTEN
08/16/2022
DOCK
ASSIGNED TO EXAMINER
08/10/2022
MAFR
APPLICATION FILING RECEIPT MAILED
01/07/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/03/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
12/30/2021
Continuous trademark protection
Get notified about every new filing that threatens ABOGENBIO or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.